The University of Chicago Header Logo

Connection

Mark Ratain to United States Food and Drug Administration

Back to Details
This is a "connection" page, showing publications Mark Ratain has written about United States Food and Drug Administration.
Mark Ratain
Connection Strength
2.804
United States Food and Drug Administration
  1. Strengthening the Food and Drug Administration Office of Clinical Pharmacology's Labeling Authority. Clin Transl Sci. 2025 Sep; 18(9):e70337.
    View in: PubMed
    Score: 0.883
  2. Are drug labels static or dynamic? Clin Pharmacol Ther. 2013 Sep; 94(3):302-4.
    View in: PubMed
    Score: 0.384
  3. Accelerated Approval Program Versus NCCN Guidelines as Mechanisms for Early Drug Access. J Natl Compr Canc Netw. 2024 08; 22(6):435-436.
    View in: PubMed
    Score: 0.205
  4. Special designations and the US Food and Drug Administration's "dual mandate". J Natl Cancer Inst. 2024 02 08; 116(2):177-179.
    View in: PubMed
    Score: 0.198
  5. Project Optimus: Is the US Food and Drug Administration Waiving Dose Optimization for Orphan Drugs? JAMA Oncol. 2023 11 01; 9(11):1489-1490.
    View in: PubMed
    Score: 0.194
  6. Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies. Br J Cancer. 2023 10; 129(9):1389-1396.
    View in: PubMed
    Score: 0.191
  7. Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message? J Clin Oncol. 2021 11 01; 39(31):3423-3426.
    View in: PubMed
    Score: 0.168
  8. Accelerated Approval of Anticancer Drugs: Lessons Learned From the Example of Olaratumab. Clin Pharmacol Ther. 2021 07; 110(1):29-31.
    View in: PubMed
    Score: 0.158
  9. Why RECIST works and why it should stay--reply to counterpoint. Cancer Res. 2012 Oct 15; 72(20):5158.
    View in: PubMed
    Score: 0.090
  10. Flushing oral oncology drugs down the toilet. J Clin Oncol. 2011 Oct 20; 29(30):3958-9.
    View in: PubMed
    Score: 0.084
  11. Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products. Clin Cancer Res. 2010 Sep 01; 16(17):4446-51.
    View in: PubMed
    Score: 0.078
  12. Nonprofit biomedical companies. Clin Pharmacol Ther. 2008 Aug; 84(2):194-7.
    View in: PubMed
    Score: 0.068
  13. Using Quantitative Approaches to Optimize Dosages for New Combinations and Subsequent Indications for Oncology Drugs. Clin Pharmacol Ther. 2025 Oct; 118(4):772-777.
    View in: PubMed
    Score: 0.054
  14. Opportunities and challenges in the development of experimental drug combinations for cancer. J Natl Cancer Inst. 2011 Aug 17; 103(16):1222-6.
    View in: PubMed
    Score: 0.021
  15. Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst. 2010 Nov 17; 102(22):1698-705.
    View in: PubMed
    Score: 0.020
  16. Learning from our patients: one participant's impact on clinical trial research and informed consent. Ann Intern Med. 1997 Jun 01; 126(11):892-7.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.